Drug Safety

Adverse Effects Toxicology FDA Counterfeit Medications Side Effects Tianeptine Substance Abuse Regulatory Actions Regulatory Affairs Clinical Trials Clinical Efficacy Adverse Events Counterfeit Pharmaceuticals Adverse Reactions Public Health Contaminated Food Military Drug Composition Fentanyl Overdose Risks Regulatory Processes Suicidal Thoughts GLP-1 Agonists FDA Warnings Illegal Drugs Medication Trust Cannabis Products Risks of Drug Use Harm Reduction Medical Research Addiction Drug Effectiveness Therapeutic Index Regulatory Compliance Quality Control Pharmaceutical Companies Chemical Analysis Market Withdrawals Market Withdrawal Adverse Drug Events Microbial Contamination Overdose Awareness Quality Standards Public Health Risks Spurious Drugs Regulation Oversight Mechanisms Opioids Corticosteroid Safety Immunogenicity Anesthetic Drugs Clinical Research Health Risks Malignancy Risks Product Quality Risks Regulatory Oversight Research Studies Medication Adverse Effects

Trimbos Issues Red Alert Over Trump‑Shaped Ecstasy Pills

Tests by the DIMS network found high levels of PMMA in the novelty tablets, a slower‑acting MDMA analogue whose delayed effects can prompt re‑dosing that raises the risk of dangerous overheating.

Utah Panel Advances Kratom Ban as Lawmakers Split on Regulation

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Ventyx’s NLRP3 Drug Cuts Inflammation Markers in Phase 2, Shares Soar

FDA Approves Weekly Leqembi Autoinjector for At-Home Maintenance in Early Alzheimer’s

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research